The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech’s Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours:
4D Molecular’s Fabry Disease Candidate Shows Early Proof-Of-Concept
4D Molecular Therapeutics Inc (NASDAQ:FDMT) has announced interim data from the Phase 1/2 trial of intravenous 4D-310 in Fabry disease patients.…
4D Molecular Therapeutics Reports Interim Results From Phase 1/2 Trial Of Its Fabry Disease Candidate: ‘AGA enzyme activity was within, or significantly above, the normal range in all three patients’
- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution
- AGA enzyme activity was
4D Molecular Therapeutics Early Sunday Highlighted Presentation Of Interim Results From Ongoing 4D-125 Phase 1/2 Trial In Patients With Advanced X-Linked Retinitis Pigmentosa At American Society Of Retina Specialists Meeting
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammation
Clinical activity observed through anatomical
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
4D Molecular To Test Its Wet AMD Gene Therapy In Patients
The FDA has signed off 4D Molecular Therapeutics’ (NASDAQ:FDMT) Investigational New Drug Application (IND) for 4D-150 for wet age-related macular degeneration…
4D Molecular Therapeutics Q2 EPS $(0.28) Up From $(2.92) YoY, Sales $14.58M Up From $3.63M YoY
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.28) per share. This is a 90.41 percent increase over losses of $(2.92) per share from the same period last year. The company reported $14.58
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)